Inflammatory Breast Cancer: Results of Antracycline-Based Neoadjuvant Chemotherapy

doi:10.1046/j.1524-4741.2003.09204.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

The Breast Journal

Volume 9 Issue 2, Pages 79 - 85

Published Online: 7 Mar 2003

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 202K) | Related Articles | Citation Tracking

Inflammatory Breast Cancer: Results of Antracycline-Based Neoadjuvant Chemotherapy

Vahit Ozmen, MD* Neslihan Cabioglu, MD* Abdullah Igci, MD* Temel Dagoglu, MD* Adnan Aydiner, MD ^‡ Mustafa Kecer, MD* Yavuz Bozfakioglu, MD* Maktav Dinçer, MD ^§ Ayhan Bilir, MD ^† and Erkan Topuz, MD ^‡

Departments of *General Surgery and ^†Histology and Embryology, Istanbul Faculty of Medicine, and Departments of ^‡Medical Oncology and ^§Radiation Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey

Address correspondence and reprint requests to: Vahit Ozmen, MD, Ataköy 11. Kisim, Zambak D, Daire: 36, Istanbul 34750, Turkey, or email: vozmen@istanbul.edu.tr.

KEYWORDS

antracycline • inflammatory breast cancer • neoadjuant chemotherapy

ABSTRACT

Abstract:Twenty-three patients with inflammatory breast cancer treated with a combined modality approach including anthracycline-based induction chemotherapy-surgery-chemotherapy-radiotherapy were reviewed. Twelve patients (52.2%) received FAC (5-fluorouracil, adriamycin, cyclophosphamide) and 11 patients (47.8%) were treated with FEC (5-fluorouracil, epirubicin, cyclophosphamide) induction chemotherapy for three cycles every 3 weeks. Surgery was followed by the initial chemotherapy or second-line chemotherapy for an additional six cycles to complete nine cycles and radiotherapy, respectively. The median overall survival (OS) time was 27 months and the median disease-free survival (DFS) was 13 months. Furthermore, patients treated with FAC induction chemotherapy have been found to have longer median OS and DFS periods compared to patients with FEC induction chemotherapy in both univariate and multivariate analysis. In conclusion, the superiority of doxorubicin-containing chemotherapy over epirubicin-containing chemotherapy should be established in larger randomized studies and more effective chemotherapeutic agents such as taxans are required for better survival rates in inflammatory breast cancer patients.

DIGITAL OBJECT IDENTIFIER (DOI)

10.1046/j.1524-4741.2003.09204.x About DOI